CORTICOSTEROID USE IN RA: Update on New Technology in the Value-based Era

Release Date: 04/10/2013
Expiration Date: 04/10/2016


Arthur L Weaver, MD, MS, FACR, MACR is Clinical Professor of Medicine Emeritus, Department of Medicine, Section of Rheumatology, University of Nebraska Medical Center
Diana Brixner, PhD, RPh is Professor and Chair, Department of Pharmacotherapy and Executive Director, Outcomes Research Center, University of Utah, Salt Lake City, UT


Dr Weaver has the following financial interest/relationship or affiliation with one or more organizations including consultant status, medical advisory boards and speakers bureaus. These companies include Amgen, Horizon Therapeutics, NiCox, Novartis, Pfizer, Primus Pharmaceuticals, Savient, and Takeda.
Dr. Brixner has no disclosures.


Physicians: Continuing Education Co, this on-line, on-demand program is accredited by the AAFP for 2 Category 1 CE credits.
Pharmacists: Institute for Post Graduate Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN: 0490-9999-13-001-H01-P Credits: 2.0 hours (0.20 ceu) Type of Activity: Knowledge. Credit will be issued for participants completing the evaluation form and scoring 70% or more on the post-test; certificates will be available through the NABP mycpemonitor site within 14 days.


This accredited activity is designed for:

Primary Care Physicians treating RA patients
Medical Directors
Directors of Pharmacy
Health Systems Pharmacists
Specialty Pharmacists

Inquiries: PHI,


DISCLOSURE OF UNLABELED USE AND DISCLAIMER: The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Institute for Post Graduate Continuing Education, the Continuing Education Company, the Performance Healthcare Initiative, or Horizon. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA).

Grant Support: This activity was supported by an independent and unrestricted education grant from Horizon Pharma.


To provide a historical context of corticosteroid use in rheumatoid arthritis, and re-assess and update the basis of current therapy, and new and emerging technology; to provide information and methods to evaluate the relative value of the components of RA therapy, and an evidence-based methodology to establish access order for individualized care in RA.


After completing this activity, the participant should be able to:

1. Describe the standard, emerging, and new technology of corticosteroid use in RA
2. Describe new technology and techniques to individualize corticosteroid use in RA therapy
3. Define how components of RA therapy provide value
4. Identify critical communication points to patients regarding the value of care components and how each relates to treatment outcomes